Allergic asthma
disease diseaseOn this page
Also known as allergic form of asthma
Summary
Allergic asthma (MONDO:0004784) is a disease and 115 clinical trials. Top therapeutic interventions include omalizumab, levocetirizine, and methacholine. A subtype of allergic respiratory disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 115
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | allergic asthma |
| Mondo ID | MONDO:0004784 |
| DOID | DOID:9415 |
| ICD-11 | 1870104478 |
| SNOMED CT | 389145006 |
| UMLS | C0155877 |
| MedGen | 102343 |
| Is cancer (heuristic) | no |
Also known as: allergic form of asthma
Disease family
This is a subtype of allergic respiratory disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › allergic asthma
Related subtypes (3): allergic rhinitis, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis
Subtypes (1): isocyanate induced asthma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 115.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 59 |
| PHASE2 | 18 |
| PHASE3 | 12 |
| PHASE4 | 11 |
| PHASE1 | 6 |
| PHASE2/PHASE3 | 4 |
| PHASE1/PHASE2 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00208234 | PHASE4 | UNKNOWN | Effect of Xolair on Airway Hyperresponsiveness |
| NCT00267202 | PHASE4 | COMPLETED | Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma |
| NCT00283504 | PHASE4 | COMPLETED | A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy |
| NCT00490425 | PHASE4 | COMPLETED | Prevention of Asthma and Allergy by Probiotic Lactobacillus GG |
| NCT00492076 | PHASE4 | COMPLETED | Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma |
| NCT00670930 | PHASE4 | COMPLETED | Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists |
| NCT00870584 | PHASE4 | COMPLETED | Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma |
| NCT00980707 | PHASE4 | COMPLETED | Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma |
| NCT01125748 | PHASE4 | COMPLETED | A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy |
| NCT02023151 | PHASE4 | COMPLETED | Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils |
| NCT04648813 | PHASE4 | COMPLETED | Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses |
| NCT04699604 | PHASE3 | RECRUITING | A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) |
| NCT05641272 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract |
| NCT00380926 | PHASE2/PHASE3 | COMPLETED | Fish Oil and Asthma in House Dust Mite Allergy |
| NCT00396409 | PHASE3 | COMPLETED | Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis |
| NCT00829179 | PHASE3 | COMPLETED | Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma |
| NCT01155700 | PHASE3 | COMPLETED | Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) |
| NCT01202903 | PHASE3 | COMPLETED | Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy |
| NCT01328886 | PHASE3 | COMPLETED | Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children |
| NCT01353755 | PHASE3 | COMPLETED | 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma |
| NCT01392859 | PHASE2/PHASE3 | COMPLETED | Characterization of the Role of Histamine in Children With Asthma |
| NCT01976208 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma |
| NCT02541331 | PHASE3 | COMPLETED | Efficacy Of Bacterial Lysate In Asthmatic Children |
| NCT04259164 | PHASE3 | COMPLETED | Anti-inflammatory Effects Glycopyrronium |
| NCT05191186 | PHASE3 | COMPLETED | Documentation of Efficacy of Intralymphatic Allergen Immunotherapy |
| NCT05400811 | PHASE3 | UNKNOWN | Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis |
| NCT05813470 | PHASE3 | COMPLETED | Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma |
| NCT05008965 | PHASE2 | RECRUITING | Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
| NCT06438757 | PHASE2 | ACTIVE_NOT_RECRUITING | Trial of JYB1904 in Patients With Allergic Asthma |
| NCT06960382 | PHASE1/PHASE2 | RECRUITING | Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma |
| NCT07342803 | PHASE2 | RECRUITING | Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients |
| NCT00406965 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma |
| NCT00434434 | PHASE2 | COMPLETED | A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma |
| NCT00485576 | PHASE2 | COMPLETED | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma |
| NCT00535028 | PHASE2 | COMPLETED | A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) |
| NCT00535431 | PHASE2 | COMPLETED | Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics |
| NCT00550797 | PHASE2 | COMPLETED | Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma |
| NCT00622362 | PHASE2 | TERMINATED | Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract |
| NCT00652223 | PHASE1/PHASE2 | COMPLETED | Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy |
| NCT00781443 | PHASE2 | COMPLETED | A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OMALIZUMAB | 4 | 21 |
| LEVOCETIRIZINE | 4 | 3 |
| METHACHOLINE | 4 | 3 |
| ALBUTEROL SULFATE | 4 | 1 |
| ECULIZUMAB | 4 | 1 |
| LEBRIKIZUMAB | 4 | 1 |
| MANNITOL | 4 | 1 |
| PEMIROLAST | 4 | 1 |
| ROFLUMILAST | 4 | 1 |
| TIPIRACIL HYDROCHLORIDE | 4 | 1 |
| LIGELIZUMAB | 3 | 1 |
| ASM-024 | 2 | 1 |
| AZD-8848 | 2 | 1 |
| BRIQUILIMAB | 2 | 1 |
| FB-825 | 2 | 1 |
| GAMMA-TOCOPHEROL | 2 | 1 |
| OZUREPRUBART | 2 | 1 |
| TREGALIZUMAB | 2 | 1 |
| CHEMBL1201026 | 0 | 1 |
| PROTOCATECHUALDEHYDE | 0 | 1 |
| FORMALDEHYDE | -1 | 1 |